Literature DB >> 19501390

Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario.

Waldo Jiménez1, Lawrence Paszat, Rachel Kupets, Andrew Wilton, Jill Tinmouth.   

Abstract

OBJECTIVE: The oncogenic HPV subtypes responsible for gynecologic malignancies have also been implicated in the development of squamous cell cancer of the anus (SCAC). SCAC is more common in women, typically presenting at an older age than gynecologic cancers. The aim of this study was determine whether women diagnosed with anal cancer are more likely to have a history of HPV-related gynecological cancer as compared to a matched control group.
METHODS: We performed a population-based, case-control study at the Institute for Clinical Evaluative Sciences (ICES) which houses the administrative databases for all residents of the province of Ontario, Canada. All women diagnosed with SCAC between 1992 and 2005, identified using ICD-9 codes (154.2, 154.3, 154.8) for anatomic site and ICD-O codes (8070-8075, 8120, 8123, 8124) for histologic subtype, were included as cases. Up to 5 female controls, matched for age, socioeconomic status, health region and number of years enrolled in the provincial health plan, were selected for each case. The exposure of interest was previous HPV-related gynecologic cancer, specifically cervical cancer, vulvar cancer and vaginal cancer. Conditional logistic regression was performed to assess the relationship between this exposure and SCAC.
RESULTS: A total of 674 women with SCAC were identified whose median age was 61. Amongst the cases, there were 7 cervical, 3 vulvar and 1 vaginal cancers compared with 5 cervical, 0 vulvar and vaginal cancers in the 3264 controls. Previous HPV-related gynecological cancer (cervical, vaginal or vulvar cancer) was significantly associated with SCAC (OR: 10.5, 95% C.I.: 3.6 to 30.3). The median time between the diagnosis of anal cancer and previous cervical cancer was 20 years.
CONCLUSIONS: Previous HPV-related gynecological cancers are strongly associated with anal cancer and may occur decades before the anal cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19501390     DOI: 10.1016/j.ygyno.2009.05.006

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Screening for Anal Cancer in Women.

Authors:  Anna-Barbara Moscicki; Teresa M Darragh; J Michael Berry-Lawhorn; Jennifer M Roberts; Michelle J Khan; Lori A Boardman; Elizabeth Chiao; Mark H Einstein; Stephen E Goldstone; Naomi Jay; Wendy M Likes; Elizabeth A Stier; Mark L Welton; Dorothy J Wiley; Joel M Palefsky
Journal:  J Low Genit Tract Dis       Date:  2015-07       Impact factor: 1.925

Review 2.  HPV and precancerous lesions of anal canal in women: systematic review.

Authors:  Maria das Graças F C Castor; Hilton Justino da Silva; Danyelly Bruneska Gondim Martins; Roberto José Vieira de Mello
Journal:  Int J Colorectal Dis       Date:  2011-08-17       Impact factor: 2.571

3.  Evaluation of anal cytology and dysplasia in women with a history of lower genital tract dysplasia and malignancy.

Authors:  Beth Cronin; Amy Bregar; Christine Luis; Steven Schechter; Paul Disilvestro; Latha Pisharodi; C James Sung; Christina Raker; Melissa Clark; Katina Robison
Journal:  Gynecol Oncol       Date:  2016-04-26       Impact factor: 5.482

Review 4.  Optimal treatment strategies for anal cancer.

Authors:  Shahab Ahmed; Cathy Eng
Journal:  Curr Treat Options Oncol       Date:  2014-09

5.  Lifestyle and reproductive risk factors associated with anal cancer in women aged over 50 years.

Authors:  K Coffey; V Beral; J Green; G Reeves; I Barnes
Journal:  Br J Cancer       Date:  2015-03-12       Impact factor: 7.640

6.  Expression of microRNAs 16, 20a, 150 and 155 in anal squamous intraepithelial lesions from high-risk groups.

Authors:  Andreia Albuquerque; Mara Fernandes; Oliver Stirrup; Ana Luísa Teixeira; Joana Santos; Marta Rodrigues; Elisabete Rios; Guilherme Macedo; Rui Medeiros
Journal:  Sci Rep       Date:  2019-02-06       Impact factor: 4.379

7.  VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).

Authors:  Jaime Feliu; Rocio Garcia-Carbonero; Jaume Capdevila; Inmaculada Guasch; Vicente Alonso-Orduna; Carlos Lopez; Pilar Garcia-Alfonso; Carmen Castanon; Isabel Sevilla; Laura Cerezo; Carles Conill; Begona Quintana-Angel; Maria E Sanchez; Ismael Ghanem; Marta Martin-Richard; Miriam Lopez-Gomez; Ana Leon; Monica Caro; Teresa Fernandez; Joan Maurel
Journal:  Cancer Med       Date:  2019-12-18       Impact factor: 4.452

8.  Multizonal anogenital neoplasia in women: a cohort analysis.

Authors:  Michelle A L Godfrey; Carmelina Cappello; Francesca Pesola; Andreia Albuquerque; Julie Bowring; Tamzin Cuming; Anke De Masi; Adam N Rosenthal; Peter Sasieni; Mayura Nathan
Journal:  BMC Cancer       Date:  2021-03-06       Impact factor: 4.430

9.  Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada.

Authors:  I Cromwell; M Gaudet; S J Peacock; C Aquino-Parsons
Journal:  BMC Health Serv Res       Date:  2016-06-27       Impact factor: 2.655

10.  Synchronous anal canal carcinoma in a heterosexual couple.

Authors:  Lucas C Mendez; Eugene Hsieh; Craig C Earle; Shun Wong
Journal:  BMC Cancer       Date:  2018-09-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.